19.5 months; P =0.06) but the difference failed to reach statistical significance; notably, in the subgroup of patients with FLT3- ITD-negative disease (88% of tested patients, n=84/96), the median OS was significantly better in the decitabine arm (38.2 vs . 25.2 months; P =0.039). 69 Importantly, in all the above studies HMA maintenance was well-tolerated.
← all excerpts
Maintenance therapy in acute myeloid leukemia: advances and controversies.
1
—
—